Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-140

If you are able to provide cardioprotection, then you will have anti-cancer synergy. The mechanisms of cardioprotection require greater concentrations of Bisantrene than anti-cancer. 79% of Oncolines cell lines at 500 nM, while meaningful cardioprotection at 1uM across a wide range of drugs. The difference between cardioprotection and synergy is that while some patients should benefit from the anti-cancer synergy, there should be significantly more that are protected from dox cardiotoxicity. Cancerous tissue is more dynamic and less predictable than non-canceroue tissues.

There are many ways to evaluate the combination efficacy in comparison to single agent Dox.